Gilde raises additional capital for healthcare service investments - Gilde Healthcare

Gilde raises additional capital for healthcare service investments

October 13, 2011

Utrecht – Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors.

“Innovative, expanding healthcare companies are in need of capital investment to support growth and this type of finance is often difficult to source from banks and governments in the current economic climate”

says Managing Partner Pieter van der Meer.

“As a value added partner providing growth capital Gilde can support the growth of various healthcare services companies.”, according to Jasper van Gorp, partner of the fund, “We are particularly focused on companies that provide quality care in a cost effective way.”

In 2010, the Gilde Healthcare Services fund invested in Stepping Stones Home & Care, a chain of small scale nursing homes for the elderly. The fund expects to announce an additional new investment in the coming weeks.

The fund complements existing Gilde Healthcare funds, which invest in companies developing medicines, diagnostic products and medical devices.

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022